Pyridine derivatives for inhibiting human stearoyl-CoA-desaturase

Details for Australian Patent Application No. 2005286653 (hide)

Owner Xenon Pharmaceuticals Inc.

Inventors Kodumuru, Vishnumurthy; Kamboj, Rajender

Agent Davies Collison Cave

Pub. Number AU-A-2005286653

PCT Pub. Number WO2006/034446

Priority 60/611,647 20.09.04 US

Filing date 20 September 2005

Wipo publication date 30 March 2006

International Classifications

A61K 31/496 (2006.01) - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene

A61P 3/06 (2006.01) Drugs for disorders of the metabolism

A61P 3/10 (2006.01) Drugs for disorders of the metabolism

A61P 43/00 (2006.01) Drugs for specific purposes, not provided for in groups

C07D 295/18 (2006.01) Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms

Event Publications

29 March 2007 PCT application entered the National Phase

  PCT publication WO2006/034446 Priority application(s): WO2006/034446

14 April 2011 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(d). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005286659-Seat repositioning device with release on control handle

2005286648-Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors